Assessment of Minimal Residual Disease in Standard-Risk AML.
暂无分享,去创建一个
Yashma Patel | Robert K Hills | Hassan Farah | P. Vyas | M. Simpson | R. Hills | N. Russell | S. Akiki | D. Grimwade | D. Linch | E. Solomon | A. Burnett | M. Griffiths | S. Freeman | A. Gilkes | Frank McCaughan | Paresh Vyas | Hassan Farah | Ellen Solomon | J. Mason | Michael Griffiths | Michael A Simpson | R. Gale | Alan K Burnett | David Grimwade | J. Jovanovic | Rosemary E Gale | David C Linch | Sylvie D Freeman | Joanne Mason | Jelena V Jovanovic | Nigel Russell | Adam Ivey | Amanda Gilkes | Angela Grech | Neesa Bhudia | Kerry Wall | Susanna Akiki | Y. Patel | A. Ivey | F. McCaughan | K. Wall | A. Grech | N. Bhudia | H. Farah | Yashma Patel | Kerry Wall | Adam Ivey
[1] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[2] M. Yao,et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations , 2007, Leukemia.
[3] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.
[4] I. Weissman,et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission , 2014, Proceedings of the National Academy of Sciences.
[5] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[6] B. Falini,et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.
[7] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[8] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] K. Döhner,et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Schrappe. Detection and management of minimal residual disease in acute lymphoblastic leukemia. , 2014, Hematology. American Society of Hematology. Education Program.
[11] D. Grimwade,et al. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. , 2016, Blood.
[12] R. Arceci. Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia , 2012 .
[13] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[14] T. Lister,et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. , 2008, Blood.
[15] R. Hills,et al. A Sensitive Risk Score for Directing Treatment in Younger Patients with AML. , 2006 .
[16] R. Hills,et al. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. , 2014, Blood.
[17] T. Haferlach,et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. , 2009, Blood.
[18] E. Hoster,et al. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse , 2014, Haematologica.
[19] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[20] F. Lo‐Coco,et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] T. Haferlach,et al. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. , 2015, Blood.
[22] R. Schlenk,et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.
[23] R. Hills,et al. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial , 2014, Leukemia.
[24] J. Cayuela,et al. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia , 2014, Haematologica.
[25] P. Guldberg,et al. Persistence of DNMT3A mutations at long‐term remission in adult patients with AML , 2014, British journal of haematology.
[26] R. Hills,et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. , 2014, Blood.
[27] Joshua F. McMichael,et al. DNMT 3 A mutations in acute myeloid leukemia , 2016 .
[28] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[29] H. Cavé,et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.
[30] D. Grimwade,et al. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? , 2014, Hematology. American Society of Hematology. Education Program.
[31] Thomas J. Hudson,et al. Corrigendum: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia , 2014, Nature.
[32] A. Kohlmann,et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. , 2012, Blood.
[33] R. Hills,et al. Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] R. Gale,et al. Should persons with acute myeloid leukemia have a transplant in first remission? , 2014, Leukemia.
[35] O. Landt,et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. , 2013, Blood.
[36] L. Bullinger,et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. , 2013, Blood.
[37] R. Hills,et al. Utility of a clinical risk score to identify high‐risk patients with de novo acute myeloid leukaemia in first remission after high‐dose cytarabine (HiDAC) based induction chemotherapy , 2013, British journal of haematology.
[38] O. Blau. DNMT3A mutations in acute myeloid leukemia , 2016 .
[39] J. Cayuela,et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin , 2014, Oncotarget.